drugset / Trial / NCT01646437

Summary

The randomized 2x2x2 factorial design placebo controlled trial will enroll 5000 participants (women 60 years or older and men 55 years or older) without known heart disease or prior stroke and without a clear indication or contraindication to any of the study medications. Eligible and consenting individuals will be randomized to receive either the active study medications or placebo (dummy pills) and will be monitored for an average of 5 years. The study will include people from at 10 countries, will be conducted by an international group of scientists and physicians and will be coordinated by the Population Health Research Institute at Hamilton Health Sciences.

Timeline

Start
2012-06
Primary completion
2020-06-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 75 mg
Subject Atenolol Other / unclassified 100 mg
Subject Hydrochlorothiazide Unknown 25 mg
Subject Ramipril Small molecule 10 mg
Subject Simvastatin Small molecule 40 mg
Subject Vitamin D Other / unclassified 60000 iu Oral